Emerging role of m6A methylation modification in ovarian cancer

Abstractm6A (N6-methyladenosine) methylation, a well-known modification in tumour epigenetics, dynamically and reversibly fine tunes the entire process of RNA metabolism. Aberrant levels of m6A and its regulators, which can predict the survival and outcomes of cancer patients, are involved in tumorigenesis, metastasis and resistance. Ovarian cancer (OC) ranks first among gynaecological tumours in the causes of death. At first diagnosis, patients with OC are usually at advanced stages owing to a lack of early biomarkers and effective targets. After treatment, patients with OC often develop drug resistance. This article reviews the recent experimental advances in understanding the role of m6A modification in OC, raising the possibility to treat m6A modification and its regulators as promising diagnostic markers and therapeutic targets for OC. Graphical Abstract

Download Full-text

ROLE OF LIPID PROFILE IN OVARIAN CARCINOMA PATIENTS

International Journal of Medical and Biomedical Studies ◽

10.32553/ijmbs.v3i8.501 ◽

2019 ◽

Vol 3 (8) ◽

Author(s):

Dr. Manisha ◽

Dr. Ruchi Jindal

Keyword(s):

Ovarian Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Ovarian Tumor ◽

Ovarian Cancer Risk ◽

Low Level ◽

Medical College ◽

Group I ◽

History Of

Background: The term "ovarian cancer" includes several different types of cancer that arise from cells of the ovary, most commonly, tumors arise from the epithelium or lining cells of the ovary. Ovarian cancer risk is positively associated with higher consumption of dietary cholesterol and eggs, and inversely associated with a higher intake of vegetables. High consumption of fats may increase circulating estrogen levels, thus increasing the possibility of cell damage and proliferation that is responsible for cancerous growth. Material & Methods: The present study was conducted at Geetanjali Medical College and Hospital, Udaipur (Rajasthan). Total 100 cases (females) attending the obstetrics and gynecology department for some gynecological and other problem were selected for this study between the age of 40-60 years, who were attending cancer centre at GEETANJALI MEDICAL COLLEGE AND HOSPITAL, Udaipur (Rajasthan). GROUP I: - It consisted of healthy females control subjects (n=50) .By routine examination and tests, we ensured that all the subjects were healthy and there were no signs and symptoms or history of ovarian tumor and diseases GROUP II: - It consisted of ovarian cancer females subjects (n=50) with a history of ovarian tumor. Results: Higher level of cholesterol, LDL, VLDL and low level of HDL are found in ovarian cancer patients. Conclusion: The present study we highlights the importance and role of serum lipid profile in diagnosis, prognosis and recurrence of the disease. The study shows that serum level of cholesterol, LDL, VLDL was elevated in patients of ovarian cancer while low level of HDL are found in ovarian cancer patients. Key words: lipid profile, ovarian cancer.

Download Full-text

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study

Diagnostics ◽

10.3390/diagnostics11030565 ◽

2021 ◽

Vol 11 (3) ◽

pp. 565

Author(s):

Angela Toss ◽

Claudia Piombino ◽

Elena Tenedini ◽

Alessandra Bologna ◽

Elisa Gasparini ◽

...

Keyword(s):

Ovarian Cancer ◽

Positive Impact ◽

Progression Free Survival ◽

Molecular Testing ◽

Wild Type ◽

Brca Mutations ◽

Multicenter Cohort Study ◽

Advanced Stages ◽

Predictive Role

Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive impact with regard to overall survival (OS) and platinum and PARP (poly (ADP-ribose) polymerase) inhibitor sensitivity. Nevertheless, molecular testing in these studies did not include copy number variation (CNV) analyses of BRCA genes. The aim of this study was to explore the prognostic and predictive role of sBRCA mutations as compared to gBRCA mutations in patients who were also tested for CNVs. Among the 158 patients included in the study, 17.09% of patients carried a pathogenic or likely pathogenic gBRCA variant and 15.19% of patients presented pathogenetic or likely pathogenic sBRCA variants and/or CNVs. Overall, 81.6% of the patients included in this study were diagnosed with a serous histotype, and 77.2% were in advanced stages. Among women diagnosed in advanced stages, gBRCA patients showed better progression-free survival and OS as compared to sBRCA and wild-type patients, whereas sBRCA patients did not show any advantage in outcome as compared to wild-type patients. In this study, the introduction of CNV analyses increased the detection rate of sBRCA mutations, and the resulting classification among gBRCA, sBRCA and wild-type patients was able to properly stratify the prognosis of OC patients. Particularly, sBRCA mutation patients failed to show any outcome advantage as compared to wild-type patients.

Download Full-text

The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction

Annals of Surgical Oncology ◽

10.1245/s10434-014-4049-z ◽

2014 ◽

Vol 22 (3) ◽

pp. 987-993 ◽

Cited By ~ 22

Author(s):

Pedro Antonio Cascales-Campos ◽

J. Gil ◽

E. Feliciangeli ◽

E. Gil ◽

A. González-Gil ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Intraperitoneal Chemotherapy ◽

Hyperthermic Intraperitoneal Chemotherapy ◽

Residual Disease ◽

Platinum Sensitive ◽

Microscopic Residual Disease

Download Full-text

The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression

Oncoscience ◽

10.18632/oncoscience.308 ◽

2016 ◽

Vol 3 (5-6) ◽

pp. 145-146 ◽

Cited By ~ 3

Author(s):

Wael M. ElShamy

Keyword(s):

Ovarian Cancer ◽

Drug Resistance

Download Full-text

A role of Cyclosporine A that suppresses multi-drug resistance (MDR) in the secondary chemotherapy drug resistant cell line of ovarian cancer

Korean Journal of Gynecologic Oncology ◽

10.3802/kjgo.2006.17.4.286 ◽

2006 ◽

Vol 17 (4) ◽

pp. 286

Author(s):

Chun San An ◽

Sung Yob Kim ◽

Chul Min Park

Keyword(s):

Ovarian Cancer ◽

Drug Resistance ◽

Cell Line ◽

Cyclosporine A ◽

Resistant Cell ◽

Resistant Cell Line ◽

Multi Drug Resistance ◽

Drug Resistant ◽

Drug Resistant Cell

Download Full-text

The predominant role of 18F-FDG PET/CT over MDCT in assessment of ovarian cancer patients

The Egyptian Journal of Radiology and Nuclear Medicine ◽

10.1016/j.ejrnm.2015.07.011 ◽

2015 ◽

Vol 46 (4) ◽

pp. 1313-1322 ◽

Cited By ~ 1

Author(s):

Hemat A. Mahmoud ◽

Haisam Atta ◽

Waleed A. Diab ◽

Lamiaa M. Eloteify ◽

Hisham Imam ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Fdg Pet ◽

Predominant Role ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

EP804 Prognostic role of second-line platinum-based therapy in recurrent platinum resistant ovarian cancer patients – data from real-world clinical practice in poland

10.1136/ijgc-2019-esgo.854 ◽

2019 ◽

Author(s):

L Bodnar ◽

P Knapp ◽

J Sznurkowski ◽

R Mądry ◽

A Gąsowska-Bodnar ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Practice ◽

Cancer Patients ◽

Real World ◽

Second Line ◽

Prognostic Role ◽

Platinum Resistant

Download Full-text

Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Pleura and Peritoneum ◽

10.1515/pp-2019-0029 ◽

2020 ◽

Vol 5 (1) ◽

Author(s):

Christos Iavazzo ◽

Alexandros Fotiou ◽

M. Tsiatas ◽

Athina Christopoulou ◽

John Spiliotis ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Cancer Recurrence ◽

Advanced Ovarian Cancer ◽

Self Report ◽

Debulking Surgery ◽

Current Management ◽

Medical Oncologists ◽

Interval Debulking Surgery

AbstractBackgroundThe aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).Methods: An email was sent to Oncologists prior to PSOGI International Symposium on Advanced Ovarian Cancer, Athens 11–13 April 2019. Doctors submitted responses on the relevant website. The self-report survey contained 17 questions.ResultsIn total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the BRCA status of their ovarian cancer patients, despite the possible differentiation of treatment based on the molecular profiling (80%).ConclusionsThe results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.

Download Full-text